A Congressional committee is sifting through drug rebate data from 12 big Medicare Part D plans. According to Congress' accounting arm, making the data public will cost the government as much as $10 billion dollars. But industry better be nervous about what happens next.
By Michael McCaughan
The House Government Oversight and Government Reform Committee is sifting through some very valuable data—information about prescritpion drug prices under...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.
The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.
ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.
New rules requiring more granular drug pricing data to be disclosed in machine-readable files will go into effect in 2026.
New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.
The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.
Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”
